Clinical Trial

ADH1 and ADH2 Disease Monitoring Study (DMS)

Study acronym: CLARIFY
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease presentation and progression through retrospective (past) and longitudinal prospective (over time into the future) data collection.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2022-02-02; most recent amendment 2026-04-27.
Status change: Recruiting → Active, Not Recruiting 2024-08-01
Trial Details
NCT Number NCT05227287
Lead Sponsor Calcilytix Therapeutics, Inc., a BridgeBio company
Conditions Autosomal Dominant Hypocalcemia
Enrollment 95 participants
Start Date 2022-01-20
Primary Completion 2028-11 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-30